Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
2.710
-0.130 (-4.58%)
At close: Aug 28, 2025, 4:00 PM
2.710
0.00 (0.00%)
After-hours: Aug 28, 2025, 4:10 PM EDT
Orchestra BioMed Holdings Revenue
Orchestra BioMed Holdings had revenue of $836.00K in the quarter ending June 30, 2025, with 7.46% growth. This brings the company's revenue in the last twelve months to $2.94M, up 41.61% year-over-year. In the year 2024, Orchestra BioMed Holdings had annual revenue of $2.64M, down -4.42%.
Revenue (ttm)
$2.94M
Revenue Growth
+41.61%
P/S Ratio
36.74
Revenue / Employee
$42,057
Employees
70
Market Cap
146.22M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.64M | -122.00K | -4.42% |
Dec 31, 2023 | 2.76M | -773.00K | -21.88% |
Dec 31, 2022 | 3.53M | 4.32M | -551.79% |
Dec 31, 2021 | -782.00K | -6.49M | -113.71% |
Dec 31, 2020 | 5.70M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OBIO News
- 2 days ago - Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology - GlobeNewsWire
- 14 days ago - Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction - GlobeNewsWire
- 16 days ago - Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 20 days ago - Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility - GlobeNewsWire
- 23 days ago - Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings - GlobeNewsWire
- 27 days ago - Orchestra BioMed Announces Pricing of $40 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Orchestra BioMed Announces Proposed Public Offering - GlobeNewsWire
- 4 weeks ago - Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewsWire